Clearmind Medicine Among Top Biopharma Companies Invited to join Washington DC, Psychedelic Summit
Key Highlights
- ➤Clearmind invited to Washington summit on accelerating psychedelic therapy system readiness
- ➤CMND-100 Phase II trials continue at Yale School of Medicine and Johns Hopkins Medicine
- ➤Clearmind targets scalable AUD treatment potentially reducing lengthy supervised dosing
- ➤Clearmind holds 32 granted patents across 19 intellectual-property families
Expert Statements
Mary-Elizabeth Gifford, Chief of Global Impact of Clearmind Medicine
“Our approach at Clearmind Medicine is to support 'system readiness' to advance a next-generation, psychedelic-derived neuroplastogen treatment model that could potentially reduce the need for lengthy and costly supervised dosing”
Mary-Elizabeth Gifford, Chief of Global Impact of Clearmind Medicine
“a scalable treatment model could open a new chapter in American mental health”
Mary-Elizabeth Gifford, Chief of Global Impact of Clearmind Medicine
“responsible patient access, not through new expensive frameworks that are yet to be built, but through America's already-existing primary care and VA resources.”
Adi Zuloff-Shani, PhD, CEO of Clearmind Medicine
“Advancing new approaches to addiction and mental health treatment requires collaboration across science, clinical research, policy, and healthcare.”
Adi Zuloff-Shani, PhD, CEO of Clearmind Medicine
“I thank the Steven & Alexandra Cohen Foundation and the leadership of BrainFutures for asking our field: 'what can we do together that cannot be done apart?'”
Vancouver, Canada, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced that it is among the invitees to join researchers, clinicians, federal agency representatives, and policymakers at the Frontiers of Mental Health and Recovery Summit being held this week in Washington D.C..
Convened by BrainFutures with the support of the Steven & Alexandra Cohen Foundation, Clearmind's Chief of Global Impact, Mary-Elizabeth Gifford, has been asked to join what BrainFutures describes as "a select group of leaders shaping the future of mental health care," through hands-on participation in two days of "collaborative working sessions" to begin to tackle the question of how to "accelerate system readiness for psychedelic therapies."
Get started
Create a free account to read the full story.